tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Shield Therapeutics Reports Strong H1 2025 Results and Global Expansion

Story Highlights
Shield Therapeutics Reports Strong H1 2025 Results and Global Expansion

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

The latest update is out from Shield Therapeutics ( (GB:STX) ).

Shield Therapeutics reported a significant increase in revenues and prescription sales for the first half of 2025, driven by the strong performance of its product ACCRUFeR® in the U.S. and successful global partnerships. The company achieved a 1.8x growth in total revenues to $21.4 million and narrowed its losses significantly, with a positive outlook to turn cash flow positive by the end of 2025. Key developments include the launch of ACCRUFeR® in Canada, a new licensing agreement in Japan, and progress in regulatory submissions for pediatric use in Europe and the U.S. These advancements position Shield Therapeutics favorably in the iron deficiency treatment market, potentially expanding access to patients worldwide.

The most recent analyst rating on (GB:STX) stock is a Hold with a £6.50 price target. To see the full list of analyst forecasts on Shield Therapeutics stock, see the GB:STX Stock Forecast page.

Spark’s Take on GB:STX Stock

According to Spark, TipRanks’ AI Analyst, GB:STX is a Neutral.

The overall stock score is primarily influenced by the company’s robust technical performance, indicating strong market momentum. However, significant financial weaknesses, including negative profitability and cash flow issues, weigh heavily on the score. Valuation concerns due to a negative P/E ratio and lack of dividend yield further impact the stock’s attractiveness.

To see Spark’s full report on GB:STX stock, click here.

More about Shield Therapeutics

Shield Therapeutics plc is a commercial-stage specialty pharmaceutical company focused on addressing iron deficiency, with or without anemia, through its innovative product ACCRUFeR®/FeRACCRU® (ferric maltol). The company has established partnerships for the commercialization of its product in various regions, including the U.S., Canada, Europe, China, Japan, and Korea, and holds patent coverage until the mid-2030s.

Average Trading Volume: 2,097,732

Technical Sentiment Signal: Hold

Current Market Cap: £73.44M

For an in-depth examination of STX stock, go to TipRanks’ Overview page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1